Skip to main content
. 2019 Oct 24;23(6):475–482. doi: 10.4196/kjpp.2019.23.6.475

Fig. 2. FoxD2-AS1 knockdown sensitizes glioma cells to temozolomide (TMZ) treatment.

Fig. 2

(A) Cell viabilities of siFoxD2-AS1 or siNC transducted glioma cells under treatment of indicated doses of TMZ. (B) Colony formation of siFoxD2-AS1 or siNC transducted glioma cells after TMZ treatment. (C) Flow cytometry analysis shown the cell apoptosis of siFoxD2-AS1 or siNC transducted glioma cells after TMZ treatment. (D) Western blot analysis of cleaved caspase-3 and Bax in glioma cells transfected with siFoxD2-AS1 or siNC after TMZ treatment. siFox, siFoxD2-AS1. *p < 0.05, **p < 0.01.